1. At least 18 years of age.
2. Histologically or cytologically confirmed adenocarcinoma of the prostate without
signet cell, or small cell features.
3. Patients must have measurable soft tissue disease per RECIST 1.1
4. DNA damage repair deficiency as assessed centrally by a gene mutation biomarker panel
(testing of de novo or archiaval tumor tissue (via central laboratory) or prior
historical testing (with Sponsor approval) using the Foundation Medicine,
FoundationOne® NGS gene panel test.
5. Consent to a saliva sample collection for a germline comparator, unless prohibited by
local regulations or ethics committee (EC) decision.
6. Serum testosterone ≤ 1.73 nmol/L (50 ng/dL) at screening.
7. Bilateral orchiectomy or ongoing androgen deprivation therapy with a
gonadotropin-releasing hormone (GnRH) agonist/antagonist (surgical or medical
8. Progressive disease at study entry defined as 1 or more of the following 3 criteria:
- A minimum of 3 rising PSA values with an interval of at least 1 week between
determinations. The screening central laboratory PSA value must be ≥ 2 μg/L (2
ng/mL) if qualifying solely by PSA progression.
- Soft tissue disease progression as defined by RECIST 1.1.
- Bone disease progression defined by PCWG3 with 2 or more new metastatic lesions
on bone scan.
9. Metastatic disease.
10. Previous treatment with 1 or 2 chemotherapy regimens including at least 1 taxane-based
regimen for metastatic (non castrate or castrate) prostate cancer. Patients may have
received radium-223 and/or cabazitaxel, or were deemed unsuitable, declined, or did
not have access to these therapies.
11. Documented disease progression (either radiographic or biochemical) on at least 1
novel hormonal therapy (enzalutamide and/or abiraterone acetate/prednisone) for the
treatment of metastatic CRPC, irrespective of prior NHT treatment for non castrate
prostate cancer or nonmetastatic (M0) CRPC.
12. Bisphosphonate or denosumab dosage must have been stable for at least 4 weeks before
day 1 for patients receiving these therapies.
13. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
14. Estimated life expectancy of ≥ 6 months as assessed by the investigator.
15. Able to swallow the study drug, have no known intolerance to study drugs or
excipients, and comply with study requirements.
16. Must use a condom when having sex with a pregnant woman from the time of the first
dose of study drug through 105 days after last dose of study drug. An additional
highly effective form of contraception must be used from the time of the first dose of
study drug through 105 days after last dose of study drug when having sex with a non
pregnant female partner of childbearing potential.
17. Must agree not to donate sperm from the first dose of study drug to 105 days after the
last dose of study drug.
18. Patients must be willing and able to comply with scheduled visits, treatment plan,
laboratory tests and other study procedures.
1. 1. Use of systemic chemotherapeutic (including but not limited to taxanes), hormonal,
biologic, or radionuclide therapy for treatment of metastatic prostate cancer (other
than approved bone targeting agents and GnRH agonist/antagonist) or any other
investigational agent within 4 weeks before day 1.
2. Prior treatment with a PARP inhibitor, cyclophosphamide, or mitoxantrone chemotherapy.
Patients who discontinued prior platinum based chemotherapy screening or whose disease previously progressed on platinum based therapy at any time
in the past are also excluded.
3. Treatment with any concurrent cytotoxic chemotherapy or investigational drug(s) within
4 weeks or 5 half lives of the drug (whichever is longer) before Day 1 and/or during
4. Radiation therapy within 3 weeks (within 2 weeks, if single fraction of radiotherapy)
before day 1.
5. Major surgery within 2 weeks before day 1.
6. Clinically significant cardiovascular disease.
7. Significant renal, hepatic, or bone marrow organ dysfunction.
8. Known or suspected brain metastasis or active leptomeningeal disease.
9. Symptomatic or impending spinal cord compression or cauda equina syndrome.
10. Diagnosis of MDS (Myelodysplastic syndromes).
11. History of another cancer within 3 years before enrollment with the exception of
nonmelanoma skin cancers, or American Joint Committee on Cancer stage 0 or stage 1
cancer that has a remote probability of recurrence in the opinion of the investigator
and the sponsor.
12. Gastrointestinal disorder affecting absorption.
13. Current or anticipated use of the following P gp inhibitors (amiodarone, carvedilol,
clarithromycin, cobicistat, darunavir, dronedarone, erythromycin, indinavir,
itraconazole, ketoconazole, lapatinib, lopinavir, propafenone, quinidine, ranolazine,
ritonavir, saquinavir, telaprevir, tipranavir, verapamil, and valspodar), P gp
inducers (avasimibe, carbamazepine, phenytoin, rifampin, and St. John's wort), or BCRP
inhibitors (curcumin, cyclosporine, elacridar [GF120918] and eltrombopag).
14. Any other acute or chronic medical or psychiatric condition (concurrent disease,
infection, or comorbidity) that interferes with ability to participate in the study,
causes undue risk, or complicates the interpretation of data, in the opinion of the
investigator or medical monitor, including recent (within the past year) or active
suicidal ideation or behavior or laboratory abnormality that may increase the risk
associated with study participation or investigational product administration or may
interfere with the interpretation of study results and, in the judgment of the
investigator, would make the patient inappropriate for entry into this study.
15. Investigator site staff members directly involved in the conduct of the study and
their family members, site staff members otherwise supervised by the investigator, or
patients who are Pfizer employees, including their family members, directly involved
in the conduct of the study.
16. Fertile male subjects who are unwilling or unable to use a highly effective method of
contraception as outlined in this protocol for the duration of the study and for at
least 105 days after the last dose of investigational product.